Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.

Svaldi, Diana Otero; Higgins, Ixavier A; Holdridge, Karen C; Yaari, Roy; Case, Michael; Bracoud, Luc; Scott, David; Shcherbinin, Sergey; Sims, John R

Svaldi, Diana Otero; Higgins, Ixavier A; Holdridge, Karen C; Yaari, Roy; Case, Michael; Bracoud, Luc; Scott, David; Shcherbinin, Sergey; Sims, John R.

Afiliación

Svaldi DO; Eli Lilly and Company Indianapolis Indiana USA.
Higgins IA; Eli Lilly and Company Indianapolis Indiana USA.
Holdridge KC; Eli Lilly and Company Indianapolis Indiana USA.
Yaari R; Eli Lilly and Company Indianapolis Indiana USA.
Case M; Eli Lilly and Company Indianapolis Indiana USA.
Bracoud L; Clario Lyon France.
Scott D; Clario San Mateo California USA.
Shcherbinin S; Eli Lilly and Company Indianapolis Indiana USA.
Sims JR; Eli Lilly and Company Indianapolis Indiana USA.

Alzheimers Dement (N Y) ; 8(1): e12313, 2022.

Article en En | MEDLINE | ID: mdl-35783453

Palabras clave

Alzheimer's disease; amyloid; atrophy; magnetic resonance imaging; solanezumab; volumetric magnetic resonance imaging

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Alzheimers Dement (N Y) Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Alzheimers Dement (N Y) Año: 2022 Tipo del documento: Article